TC
CRDL

Tejara Capital’s Cardiol Therapeutics CRDL Stock Holding History

Tejara Capital’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.42M Sell
5,113,822
-16,300
-0.3% -$20.6K 2.23% 15
2026
Q1 		$6.93M Hold
5,130,122
– – 2.28% 12
2025
Q4 		$4.89M Buy
5,130,122
+2,500,000
+95% +$2.62M 1.15% 18
2025
Q3 		$2.81M Sell
2,630,122
-635,697
-19% -$771K 1.47% 25
2025
Q2 		$4.44M Buy
3,265,819
+70,829
+2% +$82.5K 2.06% 14
2025
Q1 		$3.1M Buy
3,194,990
+79,553
+3% +$97.7K 1.2% 24
2024
Q4 		$3.99M Buy
3,115,437
+1,344,167
+76% +$2.27M 2.61% 14
2024
Q3 		$3.51M Buy
1,771,270
+49,027
+3% +$102K 1.67% 21
2024
Q2 		$3.48M Buy
1,722,243
+77,833
+5% +$165K 1.26% 29
2024
Q1 		$2.98M Buy
1,644,410
+527,734
+47% +$711K 1.09% 29
2023
Q4 		$942K Buy
1,116,676
+471,219
+73% +$400K 0.39% 47
2023
Q3 		$578K Buy
645,457
+148,396
+30% +$142K 0.33% 51
2023
Q2 		$442K Buy
497,061
+56,435
+13% +$37.3K 0.22% 59
2023
Q1 		$215K Hold
440,626
– – 0.11% 76
2022
Q4 		$225K Buy
+440,626
New +$269K 0.13% 85

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Tejara Capital's CRDL Position: Q2 2026 in Review

Tejara Capital reduced its Cardiol Therapeutics (CRDL) stake by 0.32% in Q2 2026, selling an estimated $20.6K and leaving 5,113,822 shares worth $5.42M. The position accounts for 2.23% of the portfolio, ranked #15.

Tejara Capital first reported a position in CRDL in Q4 2022 and has held it in 15 quarters since. The position peaked at $6.93M in Q1 2026. 51 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Tejara Capital held 5,113,822 shares of Cardiol Therapeutics worth $5.42M as of Q2 2026.
  • Tejara Capital sold 16,300 Cardiol Therapeutics shares in Q2 2026, an estimated $20.6K.
  • Cardiol Therapeutics made up 2.23% of Tejara Capital's portfolio in Q2 2026, its #15 holding.
  • Tejara Capital first reported a position in Cardiol Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Tejara Capital's Cardiol Therapeutics position peaked at $6.93M in Q1 2026.
  • 51 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Tejara Capital's 13F filing for Q2 2026, filed 11 Aug 2026.